A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Phase of Trial: Phase I/II
Latest Information Update: 01 Nov 2018
At a glance
- Drugs Cedazuridine/decitabine (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astex Pharmaceuticals
- 02 Aug 2018 Status changed from not yet recruiting to recruiting.
- 10 Jul 2018 Planned initiation date changed from 1 Jun 2018 to 1 Jul 2018.
- 25 Apr 2018 New trial record